Strata Critical Medical delivered a strong fourth quarter with revenue increasing 83.5% year-over-year to $66.8 million, driven by the integration of the Keystone acquisition and 35.3% organic growth in its Logistics segment. While the company reported a net loss from continuing operations of $5.4 million, Adjusted EBITDA grew significantly to $7.0 million. Management raised its full-year 2026 guidance, citing a robust M&A pipeline and favorable regulatory shifts in the transplant industry.
Total revenue grew 83.5% year-over-year to $66.8 million, significantly boosted by the Keystone acquisition and organic logistics growth.
Logistics segment revenue increased 35.3% to $49.2 million, reflecting strong organic demand from new and existing transplant customers.
Adjusted EBITDA reached $7.0 million in Q4 2025, a 547% increase compared to $1.1 million in the prior year period.
The company raised its FY 2026 revenue guidance to $260-$275 million and Adjusted EBITDA guidance to $29-$33 million.
Strata raised its full-year 2026 outlook across revenue and Adjusted EBITDA, expecting continued momentum from M&A and organic growth.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance